← Leaderboards
Sarki A. Abdulkadir
Washington University
$18,466,452
Attributed
$22,777,845
Total exposure
15
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.8M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$31,639,396 · 16
By mechanism
R01$16,012,147 · 7
P50$15,010,389 · 8
K08$616,860 · 1
Top collaborators
- Debabrata Chakravarti10 shared
- Richard R Drake5 shared
- Maha H Hussain5 shared
- Jennifer D Wu5 shared
Most similar at Washington University
Same institution · by research overlap
- Michael L Nonet$9,495,935
- Amy L Vavere$133,840
Others in their field
Top investigators on “Malignant Neoplasm Of Prostate”
- David Heimbrook · Leidos Biomedical Research, Inc.$255,843,614
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,277,106
- Walter John Curran · Thomas Jefferson University$61,298,085
- Norman Wolmark · Nsabp Foundation, Inc.$54,888,134
- James J. Dignam · University Of Chicago$48,310,409
- Laurence H Baker · University Of Michigan At Ann Arbor$43,366,962
Research focus
Malignant Neoplasm Of ProstateTumorIn VivoCellsBaseMalignant NeoplasmsRegulationProgramsProstateTumorigenicityLeadOncogenesPlayAndrogensPathway InteractionsApoptosisOverexpressionResistanceProstatic NeoplasmsMouse ModelTranscription FactorResearch PersonnelOncogenicAnimals
Grant awards (76)
SPORE in Prostate Cancer$1,881,134
P50 · FY2025 · CA · contact PI
Small molecule probes of MYC stability and function intumorigenesis$570,930
R01 · FY2025 · CA · contact PI
Project 1: Targeting the MYC Pathway in Prostate Cancer$383,608
P50 · FY2025 · CA · contact PI
Administrative, Leadership Development and Advocacy Core$366,097
P50 · FY2025 · CA · contact PI
Developmental Research Program$259,506
P50 · FY2025 · CA · contact PI
SPORE in Prostate Cancer$1,805,886
P50 · FY2024 · CA · contact PI
Small molecule probes of MYC stability and function intumorigenesis$542,383
R01 · FY2024 · CA · contact PI
Project 1: Targeting the MYC Pathway in Prostate Cancer$367,114
P50 · FY2024 · CA · contact PI
Administrative, Leadership Development and Advocacy Core$350,478
P50 · FY2024 · CA · contact PI
Developmental Research Program$249,218
P50 · FY2024 · CA · contact PI
SPORE in Prostate Cancer$1,758,412
P50 · FY2023 · CA · contact PI
Small molecule probes of MYC stability and function intumorigenesis$559,511
R01 · FY2023 · CA · contact PI
Project 1: Targeting the MYC Pathway in Prostate Cancer$376,099
P50 · FY2023 · CA · contact PI
Administrative, Leadership Development and Advocacy Core$325,863
P50 · FY2023 · CA · contact PI
Developmental Research Program$241,341
P50 · FY2023 · CA · contact PI
SPORE in Prostate Cancer$1,759,336
P50 · FY2022 · CA · contact PI
Small molecule probes of MYC stability and function intumorigenesis$559,511
R01 · FY2022 · CA · contact PI
Tumor immune and glycan biomarkers for progressive prostate cancer$552,871
R01 · FY2022 · CA
Project 1: Targeting the MYC Pathway in Prostate Cancer$376,100
P50 · FY2022 · CA · contact PI
Administrative, Leadership Development and Advocacy Core$325,972
P50 · FY2022 · CA · contact PI
Developmental Research Program$241,339
P50 · FY2022 · CA · contact PI
SPORE in Prostate Cancer$1,656,783
P50 · FY2021 · CA · contact PI
Small molecule probes of MYC stability and function intumorigenesis$567,361
R01 · FY2021 · CA · contact PI
Tumor immune and glycan biomarkers for progressive prostate cancer$561,790
R01 · FY2021 · CA
Project 1: Targeting the MYC Pathway in Prostate Cancer$363,968
P50 · FY2021 · CA · contact PI
Administrative, Leadership Development and Advocacy Core$297,044
P50 · FY2021 · CA · contact PI
Developmental Research Program$233,555
P50 · FY2021 · CA · contact PI
Tumor immune and glycan biomarkers for progressive prostate cancer$529,005
R01 · FY2020 · CA
Tumor immune and glycan biomarkers for progressive prostate cancer$513,134
R01 · FY2019 · CA
Integrating Epigenomic and Nuclear Receptor Signaling in Castrate Resistant Prostate Cancer$428,683
R01 · FY2019 · CA
EPHB4 Receptor Kinase as a Target in Prostate Cancer$255,425
P50 · FY2019 · CA · contact PI
Tumor immune and glycan biomarkers for progressive prostate cancer$563,176
R01 · FY2018 · CA
Integrating Epigenomic and Nuclear Receptor Signaling in Castrate Resistant Prostate Cancer$441,943
R01 · FY2018 · CA
EPHB4 Receptor Kinase as a Target in Prostate Cancer$287,381
P50 · FY2018 · CA · contact PI
Integrating Epigenomic and Nuclear Receptor Signaling in Castrate Resistant Prostate Cancer$441,943
R01 · FY2017 · CA
EPHB4 Receptor Kinase as a Target in Prostate Cancer$288,070
P50 · FY2017 · CA · contact PI
Role of Oncogenic Kinase Pim-1 in Prostate Cancer$284,744
R01 · FY2017 · CA · contact PI
Integrating Epigenomic and Nuclear Receptor Signaling in Castrate Resistant Prostate Cancer$441,943
R01 · FY2016 · CA
Prostate Cancer Recurrence: models and mechanisms$362,601
R01 · FY2016 · CA · contact PI
EPHB4 Receptor Kinase as a Target in Prostate Cancer$285,799
P50 · FY2016 · CA · contact PI
Role of Oncogenic Kinase Pim-1 in Prostate Cancer$284,744
R01 · FY2016 · CA · contact PI
Integrating Epigenomic and Nuclear Receptor Signaling in Castrate Resistant Prostate Cancer$441,943
R01 · FY2015 · CA
Prostate Cancer Recurrence: models and mechanisms$362,601
R01 · FY2015 · CA · contact PI
Role of Oncogenic Kinase Pim-1 in Prostate Cancer$284,744
R01 · FY2015 · CA · contact PI
EPHB4 Receptor Kinase as a Target in Prostate Cancer$274,861
P50 · FY2015 · CA · contact PI
Prostate Cancer Recurrence: models and mechanisms$351,723
R01 · FY2014 · CA · contact PI
Role of Oncogenic Kinase Pim-1 in Prostate Cancer$276,202
R01 · FY2014 · CA · contact PI
Prostate Cancer Recurrence: models and mechanisms$343,891
R01 · FY2013 · CA · contact PI
Role of Oncogenic Kinase Pim-1 in Prostate Cancer$280,943
R01 · FY2013 · CA · contact PI
Prostate Cancer Recurrence: models and mechanisms$372,420
R01 · FY2012 · CA · contact PI
Modeling Prostate Tumorigenesis$233,032
R01 · FY2012 · CA · contact PI
Role of Oncogenic Kinase Pim-1 in Prostate Cancer$282,664
R01 · FY2011 · CA · contact PI
Modeling Prostate Tumorigenesis$233,032
R01 · FY2011 · CA · contact PI
Role of Oncogenic Kinase Pim-1 in Prostate Cancer$291,406
R01 · FY2010 · CA · contact PI
Modeling Prostate Tumorigenesis$230,554
R01 · FY2010 · CA · contact PI
Role of Oncogenic Kinase Pim-1 in Prostate Cancer$291,406
R01 · FY2009 · CA · contact PI
Modeling Prostate Tumorigenesis$230,554
R01 · FY2009 · CA · contact PI
Modeling Prostate Tumorigenesis$130,472
R01 · FY2009 · CA · contact PI
Role of Oncogenic Kinase Pim-1 in Prostate Cancer$291,406
R01 · FY2008 · CA · contact PI
Modeling Prostate Tumorigenesis$230,554
R01 · FY2008 · CA · contact PI
Modulation of Androgen Signaling in Prostate Cancer$297,965
R01 · FY2007 · CA · contact PI
Role of Oncogenic Kinase Pim-1 in Prostate Cancer$291,406
R01 · FY2007 · CA · contact PI
Modulation of Androgen Signaling in Prostate Cancer$305,446
R01 · FY2006 · CA · contact PI
Modeling Prostate Cancer by Conditional Gene Targeting$229,854
R01 · FY2006 · CA · contact PI
Modulation of Androgen Signaling in Prostate Cancer$290,955
R01 · FY2005 · CA
Modeling Prostate Cancer by Conditional Gene Targeting$233,883
R01 · FY2005 · CA
Modulation of Androgen Signaling in Prostate Cancer$297,250
R01 · FY2004 · CA
Modeling Prostate Cancer by Conditional Gene Targeting$225,838
R01 · FY2004 · CA
ROLE OF TRANSCRIPTION FACTOR EGR1 IN PROSTATE CANCER$123,372
K08 · FY2004 · CA
Modeling Prostate Cancer by Conditional Gene Targeting$225,838
R01 · FY2003 · CA
ROLE OF TRANSCRIPTION FACTOR EGR1 IN PROSTATE CANCER$123,372
K08 · FY2003 · CA
Modeling Prostate Cancer by Conditional Gene Targeting$247,892
R01 · FY2002 · CA
ROLE OF TRANSCRIPTION FACTOR EGRL IN PROSTATE CANCER$123,372
K08 · FY2002 · CA
ROLE OF TRANSCRIPTION FACTOR EGRL IN PROSTATE CANCER$123,372
K08 · FY2001 · CA
ROLE OF TRANSCRIPTION FACTOR EGRL IN PROSTATE CANCER$89,645
K08 · FY2000 · CA
ROLE OF TRANSCRIPTION FACTOR EGRL IN PROSTATE CANCER$33,727
K08 · FY2000 · CA